Venaxis, Inc. Business Update

CASTLE ROCK, Colo., June 22, 2015 /PRNewswire/ -- Venaxis®, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on advancing commercialization of its CE Marked APPY1® Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low risk for appendicitis, today announced that the Company will host an investor conference call to provide an update on regulatory and business matters, on Wednesday, June 24, 2015, at 4:30 p.m. ET. The conference call will be hosted by Steve Lundy, President and CEO.

A live audio webcast will be accessible via the Investor Relations section of the Venaxis website, www.venaxis.com/webcast/. Participants and investors may also access the conference call by dialing 1-888-359-3627 (U.S.) or 1-719-325-2354 (Toll - International).  

A replay of the call will be available approximately an hour after the end of the conference call on the Company's website. To access the webcast, please visit the investor relations section of the Venaxis website at www.venaxis.com/webcast/.

About Venaxis, Inc. 
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid blood based test for appendicitis. This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low probability for acute appendicitis, allowing for more conservative patient management. The APPY1 Test is being developed initially for pediatric, adolescent, and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging. While the FDA clearance process and status is being evaluated, a limited commercial launch for the APPY1 Test is advancing in select European countries. For more information, visit www.venaxis.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to obtain FDA clearance or approval for the APPY1 Test, maintain CE Marking, cost effectively manufacture and generate revenues from the APPY1 Test at a profitable price point in Europe, execute agreements required to successfully advance the company's objectives, retain the management and scientific team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, realize value of intangible assets, obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise, and deal with general business conditions and competition. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis' recent filings with the SEC, including its Form 10-K for the year ended December 31, 2014, filed with the SEC on March 30, 2015.

Venaxis and APPY1 are registered trademarks and APPYAnalytics is a trademark of Venaxis, Inc.

Contact Jed Mahan, jmahan@venaxis.com; (303) 794-2000 Ext. 255

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/venaxis-business-update-300102761.html

SOURCE Venaxis, Inc.